Testing effectiveness (Phase 2)Study completedNCT03906058
What this trial is testing
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 39